Back to Agenda
Leveraging New Meeting Opportunities in PDUFA VII: Experiences with Type D and INTERACT
Session Chair(s)
Victoria Dohnal, RAC
Director, Regulatory Policy, North America, Johnson & Johnson, United States
This forum will address experience to date with new meeting types included in PDUFA VII, including Type D and INTERACT. Forum participants will evaluate successes, opportunities for improvement, and discuss how learnings can be shared.
Learning Objective : Evaluate experiences to date with Type D and INTERACT meetings included in PDUFA VII; Identify opportunities to improve implementation of new meeting types to promote innovation and optimize FDA-Sponsor Interactions.
Speaker(s)
Industry Update
Victoria Dohnal, RAC
Director, Regulatory Policy, North America, Johnson & Johnson, United States
FDA Update
Christy L. Cottrell
Chief, Project Management Staff, ORO, DRO-OD, CDER, FDA, United States
FDA Update
Adriane Fisher, MBA, MPH
Regulatory Project Manager, OTP, CBER, FDA, United States
Industry Update
Alex May, MS
Regulatory Policy and Advocacy, Genentech, United States
Have an account?